IMR Press / CEOG / Volume 46 / Issue 2 / DOI: 10.12891/ceog4423.2019

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Do first trimester maternal serum follistatin like 3 levels predict preeclampsia and/or related adverse pregnancy outcomes?
Show Less
1 Department of Obstetrics and Gynecology, Meram Faculty of Medicine, Necmettin Erbakan University, Konya
2 Department of Obstetrics and Gynaecology, Marmara University Pendik Education and Research Hospital, Istanbul
3 Department of Biochemistry, Dr. Lutfi Kirdar Kartal Education and Research Hospital, Istanbul ;
4 Department of Obstetrics and Gynaecology, Kirklareli University, Kirklareli, Turkey
*Correspondence: (F. ERCAN)
Clin. Exp. Obstet. Gynecol. 2019, 46(2), 195–200;
Published: 10 April 2019

Purpose of Investigation: The aim of this study is to evaluate whether first trimester maternal serum follistatin like 3 (FSTL3) levels can be used to predict preeclampsia and related obstetric complications. Materials and Methods: The serum levels of FSTL3, pregnancy associated plasma protein A (PAPP-A), and free β-hCG were determined in the first trimester from a sample of 180 pregnant women. All patients had first- and second-trimester ultrasound evaluations. The pregnancy outcome was defined as ‘adverse’ if one of the following outcomes were observed: fetal death, preeclampsia, pregnancy-induced hypertension (PIH), delivery of a small infant for gestational age (SGA) or preterm delivery. Results: FSTL3 levels were not significantly different for preeclampsia and related adverse obstetric outcomes compared to the control group (p < 0.05). Only PAPP-A MoM values were lower in the adverse obstetric outcome group than in the control (p = 0.040). There was no significant association among FSTL3 levels and the presence of any complications, according to our ROC curve analyses (p = 0.846). Conclusions: First trimester FSTL3 levels are not predictive for preeclampsia or adverse pregnancy outcomes.

Adverse outcome
First trimester
Follistatin like 3
Figure 1.
Back to top